Streetbeat News

Products Services

MURA

Mural Oncology is set to host a Virtual Investor Day to discuss new clinical insights into their late-stage trials of nemvaleukin, with key data readouts expected in 2025. An IND submission for their IL-18 program is planned for Q4 2025.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 11:20 am

TFFP

TFF Pharmaceuticals has published preclinical data in the Journal of Drug Delivery Science and Technology, showcasing the superiority of its TFF technology for pulmonary drug delivery. The study highlights better drug distribution and rapid disaggregation of TFF powders compared to other methods.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 11:15 am

IAS

Integral Ad Science (IAS) has announced that it will now offer its misinformation brand safety and suitability reporting for advertisers running campaigns on YouTube. This service will help advertisers verify the safety and suitability of their digital media investments by detecting misinformation content on YouTube.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 11:15 am

EYEN

Eyenovia has launched and made commercially available Clobetasol Propionate Ophthalmic Suspension 0.05% in the US. This FDA-approved treatment is for post-operative inflammation and pain following ocular surgery.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 11:12 am

GANX

Gain Therapeutics is hosting a webinar to discuss data from its Phase 1 study of GT-02287 for Parkinson's Disease, which was recently presented at a major international congress.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 11:07 am

BYDDF

BYDDY

BYD Co. has reached a significant milestone by producing its 9 millionth new energy vehicle (NEV), a red Yangwang U9 supercar. This achievement highlights BYD's rapid growth in the NEV market, having produced its 8 millionth NEV just two months prior. The company has also surpassed Tesla in battery electric vehicle sales in the last quarter of 2023.

Portfolio Pulse from Anan Ashraf

September 26, 2024 | 11:06 am

KTTA

Pasithea Therapeutics reported positive safety, tolerability, and preliminary efficacy data from its Phase 1 trial of PAS-004. A patient with stage 3 colon cancer showed stable disease with no adverse events, supporting the drug's potential as a MEK inhibitor.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 11:05 am

ACXP

Acurx Pharmaceuticals (NASDAQ:ACXP) announced promising data on ibezapolstat, showing its positive effects on the gut microbiome and potential in treating C. difficile infections. The drug demonstrated favorable pharmacokinetics and efficacy against B. anthracis, including resistant strains.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 11:04 am

BIIB

SAGE

Biogen has terminated its rights under the collaboration with Sage Therapeutics for the SAGE-324 program following negative Phase 2 study results. The companies have discontinued further development of SAGE-324 for essential tremor.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 11:03 am